Synairgen plc
('Synairgen' or the 'Company')
Results of Annual General Meeting and Appointment of New
Chairman
Southampton, UK - 10 October 2024:
Synairgen plc (LSE: SNG), the respiratory company developing
SNG001, an investigational formulation for inhalation containing
the broad-spectrum antiviral protein interferon beta, announces the
results of voting at its Annual General Meeting today. All
resolutions proposed at its Annual General Meeting were
passed.
The full results of the proxy voting
and text of the resolutions can be viewed by visiting the Company's
website at www.synairgen.com/investors/aim-rule-26.
Following the announcement on 18
September, Dr. Mark Parry-Billings has now succeeded Simon Shaw as
Chairman of the Board of Directors, effective immediately post
today's AGM. Dr. Parry-Billings is an accomplished international
biotech and pharmaceutical executive with a successful track record
of more than 30 years heading R&D and leading businesses. Most
recently, he served as Global Head of Drug Development at Chiesi.
Prior to this, he served as CEO of Topigen Pharmaceuticals until
its acquisition by Pharmaxis in 2010. Mark has deep expertise in
respiratory therapeutics and drug delivery to the lungs, notably
having led multiple novel respiratory assets from early stage
through clinical development and to market approvals, with a
primary focus on inhaled drug delivery.
For
further enquiries, please contact:
Synairgen plc
Media@synairgen.com
Tel: + 44 (0) 23 8051
2800
Cavendish Capital Markets Limited (NOMAD and Joint
Broker)
Geoff Nash, Camilla Hume, Trisyia
Jamaludin (Corporate Finance)
Sunila de Silva (ECM)
Nigel Birks - Life Science
Specialist Sales
Tel: + 44 (0) 20 7220
0500
Deutsche Numis (Joint Broker)
Freddie Barnfield, Duncan Monteith,
Euan Brown
Tel: + 44 (0) 20 7260
1000
ICR
Consilium (Financial Media and Investor
Relations)
Mary-Jane Elliott, Namrata Taak,
Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for
Editors
About Synairgen
Synairgen is a UK-based respiratory
company focused on drug discovery and the development of SNG001
(inhaled interferon beta) as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.
Millions of people globally are
hospitalised every year due to viral lung infections and there are
currently no approved antiviral therapies for the majority of these
patients. Synairgen is developing SNG001 to address this
need.
Synairgen is quoted on AIM (LSE:
SNG). For more information about Synairgen, please see
www.synairgen.com